Analytical Data
-
Gene name
NOR1
- Application
-
Alternative Names
NR4A3; NR4-A3; CHN; TEC; CSMF; MINOR; NOR1; Nuclear Receptor Subfamily 4,Group A,Member 3; Mitogen-induced nuclear orphan receptor; Nuclear hormone receptor NOR-1
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P51179
-
Expression Region
Glu29~Pro145
-
Molecular Weight
17kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NOR1, or nuclear receptor subfamily 4 group A member 1, is a member of the nuclear receptor superfamily and plays critical roles in various physiological processes, including metabolism, cardiovascular function, and reproductive health. As a transcription factor, NOR1 regulates the expression of genes involved in these processes by responding to various signaling pathways, including those activated by hormones and nutrient availability. Its significance has been underscored by studies linking NOR1 dysregulation to metabolic disorders, such as obesity and type 2 diabetes, as well as cardiovascular diseases. Recent investigations into the functional properties of recombinant NOR1 have focused on its ligand-binding capabilities and transcriptional activity, identifying potential therapeutic targets for intervention in related pathologies. By generating and characterizing recombinant NOR1 protein, researchers aim to unravel its intricate mechanisms of action and evaluate its potential as a drug target, especially in metabolic and cardiovascular diseases. Understanding NOR1's role in gene regulation and cellular signaling not only provides insight into its physiological importance but also opens avenues for the development of novel therapeutic strategies that could mitigate the impact of diseases associated with NOR1 malfunction. This research is vital in elucidating how NOR1 contributes to health and disease, ultimately paving the way for innovative treatments that harness its biological functions.
